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Abstract 
Context: Children with congenital adrenal hyperplasia (CAH) and adrenal insufficiency 
(AI) require daily hydrocortisone replacement with accurate dosing.
Objective: Prospective study of efficacy and safety of hydrocortisone granules in children 
with AI and CAH monitored by 17-OHP (17-hydroxyprogesterone) saliva profiles.
Methods: Seventeen children with CAH (9 male) and 1 with hypopituitarism (male), 
aged from birth to 6 years, had their hydrocortisone medication changed from pharmacy 
compounded capsules to hydrocortisone granules. Patients were followed prospectively 
for 2 years. In children with CAH, the therapy was adjusted by 17-OHP salivary profiles 
every 3 months. The following parameters were recorded: hydrocortisone dose, height, 
weight, pubertal status, adverse events, and incidence of adrenal crisis.
Results: The study medication was given thrice daily, and the median duration of 
treatment (range) was 795 (1–872) days, with 150 follow-up visits. Hydrocortisone doses 
were changed on 40/150 visits, with 32 based on salivary measurements and 8 on serum 
17-OHP levels. The median daily mg/m2 hydrocortisone dose (range) at study entry for 
the different age groups 2–8  years, 1  month to 2  years, <28  days was 11.9 (7.2–15.5), 
9.9 (8.6–12.2), and 12.0 (11.1–29.5), respectively, and at end of the study was 10.2 (7.0–
14.4), 9.8 (8.9–13.1), and 8.6 (8.2–13.7), respectively. There were no trends for accelerated 
or reduced growth. No adrenal crises were observed despite 193 treatment-emergent 
adverse events, which were mainly common childhood illnesses.
Interpretation: This first prospective study of glucocorticoid treatment in children with 
AI and CAH demonstrates that accurate dosing and monitoring from birth results in 
hydrocortisone doses at the lower end of the recommended dose range and normal 
growth, without occurrence of adrenal crises.


































































e1434  The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 3
The most common cause of adrenal insufficiency (AI) in 
young children is congenital adrenal hyperplasia (CAH) (1). 
Patients require lifelong glucocorticoid replacement therapy 
(2). The recommended therapy in childhood is hydrocor-
tisone given 3 to 4 times daily (2). It is necessary to ad-
just the glucocorticoid dose in the growing child, and timed 
hormone measurements, including 17-hydroxyprogesterone 
(17-OHP), are used to monitor CAH control (2). Successful 
therapy of AI in childhood requires access to a multidiscip-
linary team of health care professionals, regular clinic visits, 
and reliable medication to avoid adverse effects (3). Until 
2018, the lowest available licenced preparations of hydro-
cortisone were 10 mg tablets in Europe and 5 mg tablets 
in the United States. As scored tablets are licensed to be 
divided into halves, the lowest possible available dose was 
5 mg (Europe) and 2.5 mg (US), respectively. However, these 
doses are not appropriate to treat neonates, infants, and 
young children with AI, as they require a daily dose of 10 to 
15 mg/m2, with single doses as low as 0.5 mg (4). Crushed 
hydrocortisone tablets suspended in water are often used in 
some countries (2), though accurate dosing is not possible, 
as hydrocortisone does not dissolve well in water and may 
adhere to plastic material when applied with syringes (5, 6). 
Another common practice in pharmacies is to compound 
hydrocortisone, which is often mixed with sucrose to over-
come the inherent bitterness of hydrocortisone. However, 
a German study demonstrated that up to 25% of com-
pounded batches do not fulfil the acceptance criteria of the 
European Pharmacopeia in uniformity of net mass or drug 
content, or are labeled inaccurately (7). In Europe, hydrocor-
tisone granules have now become licensed for children with 
AI from birth to 18 years of age and are available in low 
doses of 0.5, 1, 2, and 5 mg. They were developed to address 
the age group-specific needs of neonates, infants, and young 
children (8, 9). As part of the development program, a single 
dose clinical trial was undertaken in neonates, infants, and 
children under 6 years of age with AI, the majority of whom 
had CAH (10). The children were then invited to participate 
in a prospective follow-up study of continued treatment 
with hydrocortisone granules. It was not possible to include 
a control group for the hydrocortisone granules, as there 
is no licenced formulation providing a hydrocortisone dose 
below 5  mg and the regulatory authorities recommended 
against using compounded medication. This manuscript re-
ports the results of this prospective study.
Methods
Protocol
A prospective follow-up study with patients who had been 
recruited from a previous single-dose pharmacokinetic 
study of hydrocortisone granules was performed over a 
duration of 2.5 years. The first 3 clinic visits were scheduled 
monthly, followed by visits every three months (3-monthly). 
Children who withdrew early were included in baseline and 
safety analyses but excluded from further analysis.
Patients
A total of 18 patients that included 10 male, all Caucasian, 
1 male with congenital hypopituitarism, and the others with 
genetically confirmed CAH, were included in the study. All of 
them successfully completed the previous study with single 
dosing of the study medication, whose inclusion criteria were 
age <6 years, confirmed AI (inappropriately low cortisol level), 
receiving appropriate adrenocortical replacement therapy 
(hydrocortisone +/- fludrocortisone), adequately hydrated 
and nourished status at the screening visit, and the ability 
of the parents/caregivers to understand and give written, in-
formed consent according to the German Medicinal Product 
Act (AMG §40 3b) (1). Exclusion criteria included: clinical 
signs of acute infection; fever or current adrenal crisis (al-
though subjects could be re-evaluated for eligibility after 
acute episodes); inability of the child to take oral therapy; 
any surgical or medical condition that, in the opinion of the 
investigator, could have placed the subject at higher risk from 
his/her participation in the study; and parents/caregivers of 
subjects unwilling to consent to the saving or propagation of 
pseudonymized medical data for study reasons. The patients 
were enrolled into one of 3 cohorts, according to their age at 
study entry in the previous study (Table 1).
Treatment
The hydrocortisone dose was given according to the 
manufacturer’s instructions (Alkindi Summary of Product 
Characteristics). Children´s hydrocortisone medication was 
changed from pharmacy compounded capsules to hydro-
cortisone granules, continuing the same dose. Patients 
were followed prospectively for 2 years. In children with 
CAH, therapy was adjusted by 17-OHP salivary profiles 
timed prior to each dose of one day every three months. 
Compliance with the intake of hydrocortisone granules was 
calculated on the basis of the number and strength of cap-
sules dispensed and returned, the number of days between 
visits, and the daily dose of hydrocortisone prescribed for 
the time interval.
Measurements
At each visit, the following measurements were taken: 
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examination including pubertal status. In CAH patients, 
salivary 17-OHP levels were used for dose adjustments 
in accordance with the clinic’s standard practice, based 
on at-home sampling every 3  months starting from 
3–6  months of age. Patients were trained to chew on a 
swab (Salivette, Sarstedt, Germany) for at least 3 min-
utes immediately before each dose of hydrocortisone for 
2 consecutive days, that is, 6 samples. In children below 
1 year of age, the parents/caregivers wiped the oral cavity 
with the Salivette swab to collect saliva. Serum measure-
ments of 17-OHP were only made if the child was unable 
to provide a 17-OHP saliva profile or when renin levels 
were measured annually as part of routine clinical care. 
Blood sampling was not timed prior to hydrocortisone in-
take, as it was performed when children visited the out-
patient clinic. Adverse events following the first intake of 
study medication, including stress dosing, were recorded 
at every visit.
Calculations of weight and height standard 
deviation scores, and parental target height 
standard deviation score
Weight and height standard deviation (SD) scores were based 
on German KIGGS-Data (11). The parental target height 
was calculated using the method of Hermanussen/Cole (12).
Methods of hormone measurements
Hormones were measured using the clinic’s standard 
practices. Serum 17-OHP was measured using the IDS-
iSYS Multi-Discipline Automated System 17-OHP assay 
(Immunodiagnostic Systems Limited, Tyne & Wear, 
United Kingdom) with a lower limit of quantification 
(LLOQ) 0.31  ng/mL. Salivary 17-OHP was measured 
using the Demeditec free 17-OHP in saliva ELISA kit 
(Demeditec Diagnostics GmbH, Kiel, Germany). Both 
measurements were done according to the manufacturer’s 
instructions. Performance parameters for the assays 
(serum/saliva) are intra-assay variability: 2.4%/5.2%; 
interassay variability: 6.2%/5.3%; and LLOQ: 0.3  ng/
ml/11.3 pg/mL.
Hydrocortisone dosing and dose titration
Hydrocortisone dose in newborn babies was determined by 
the treatment center. This was 2 mg hydrocortisone thrice 
daily for the main center, while the 2 newborns from sat-
ellite centers were treated with 2-1-1  mg and 1-1-1  mg 
daily, respectively. Initially, the dose was adjusted by serum 
17-OHP, reducing the dose as soon as serum 17-OHP was 
normalized to a minimum of 2-1-1 mg in 2 patients and 
1-1-1 mg in the third newborn baby. From about 6 months 
of age, dosing of hydrocortisone was adjusted using timed 
saliva 17-OHP profiles in patients at the central clinic, while 
the patients from satellite centers were monitored by serum 
17-OHP. The central clinic has established daytime specific 
target ranges for predose salivary 17-OHP based on the ref-
erence range for healthy children (3.0–32.9 pg/mL). Target 
ranges for CAH patients were defined as follows:
 •  Between 2:00 am and 10:00 am: <2.5-fold of the upper 
reference limit was considered “overtreatment,” 2.5- 
to 5-fold was considered “good disease control,” 5- to 
10-fold was considered “acceptable,” and >10-fold 
levels were considered “undertreatment.”
 • Between 10:00 am and 2:00 am the ranges were reduced 
by 50%, as follows: <1.25-fold of the upper reference 
limit was considered “overtreatment,” 1.25- to 2.5-fold 
was considered “good disease control,” 2.5- to 5-fold 
was considered “acceptable,” and >5-fold levels were 
considered “undertreatment.”
Hydrocortisone doses were adjusted according to the 
predose 17-OHP salivary profiles. If the value for 17-OHP 
was out of range, the dose 8 hours before that sample time 
point was adjusted. Doses were adjusted by the smallest 
increment possible, usually 0.5 to 1.0  mg, depending on 
how close the current daily hydrocortisone dose was to the 
target range of 10 mg/m2/day. Hydrocortisone dose in mg 
Table 1. Patient characteristics at baseline, median (range): classification in 3 cohorts according to age at study entry in 
previous study
Cohort 1 Cohort 2 Cohort 3 Overall
Number n = 9 n = 6 n = 3 n = 18
Female/male 4/5 2/4 2/1 8/10
Age (days) 1316 (1077–2084) 748 (394–923) 46 (36–145) 1000 (36–2084)
Age (months) 43 (35–68) 25 (13–30) 2 (1–5) 33 (1–68)
BMI (kg/m2) 16.4 (13.7–22.1) 17.5 (16.4–20.1) 16.0 (13.2–16.8) 16.83 (13.2–22.1)
BSA (m2) 0.71 (0.58–0.84) 0.56 (0.44–0.60) 0.27 (0.20–0.33) 0.59 (0.20–0.84)
Cohort 1: 2 to <6 years; cohort 2: 1 month to 2 years; and cohort 3: <28 days.
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per body surface area was always calculated but was not 
the sole basis for dose adjustment.
Sick day rules, adrenal crisis
Parents/caregivers were trained in using the clinic’s standard 
sick day rules for children with AI in case of fever and 
illness, and increased their daily hydrocortisone dose ac-
cording to local guidelines: for fever >38°C, a double 
hydrocortisone dose; for fever >39°C, a triple dose; and for 
fever >40°C, a 5-fold dose. A repeated full dose was recom-
mended in case of vomiting, and a prednisolone suppository 
(100 mg) and urgent presentation to a doctor was indicated 
when the vomiting continued. Adrenal crisis was defined 
as a profound impairment of general health and at least 
2 of the following conditions: hypotension (systolic blood 
pressure <100 mmHg), nausea or vomiting, severe fatigue, 
hyponatremia, hypoglycemia, and hyperkalemia (13).
Ethics
The study was conducted in accordance with the ethical 
principles in the Declaration of Helsinki (1996) and in ac-
cordance with International Council for Harmonisation 
Good Clinical Practice and the Independent Ethics 
Committee (study number at the local ethics committee 
15/0375 – EK 15) and BfArM (the German regulatory 
authority) requirements. All parents/caregivers gave 
their written informed consent and all children >3 years 
of age were informed separately about the study proced-
ures. Subjects remained enrolled in the study unless they 
met the study withdrawal criteria or until hydrocorti-
sone granules became commercially available.
Results
Patients and visits
Eighteen patients were recruited. In total, 6 patients 
withdrew during the study: 4 withdrew within the first 
month and their data were only included in the baseline 
and safety analysis; 1 patient withdrew after 5  months 
and has data included but did not attend the final visit, 
and the growth charts therefore exclude this patient; and 
1 patient withdrew before first dosing, resulting in inclu-
sion of only demographic data. One patient also withdrew 
before dosing, but subsequently re-enrolled, and the re-
spective data are included from that date onwards. One 
male patient with hypopituitarism was only included in the 
demographic data and safety data analysis, as growth was 
impaired by the underlying condition. Seventeen patients (8 
females, 9 males), with genetically confirmed classic CAH, 
had salt wasting CAH and were additionally treated with 
fludrocortisone. All withdrawals were within the older pa-
tient cohorts 1 (n = 5) and 2 (n = 1) and were related to dif-
ficulties adapting from sweetened pharmacy-compounded 
powder to tasteless dry granules for the administration of 
the nighttime dose while sleeping. A protocol amendment 
was made during the study to allow for the use of soft food 
for administration of the granules. Study follow-up was up 
to 2.5  years: median (range) 795  days (1–872  days). Of 
the 12/17 children with CAH who received hydrocortisone 
granules for more than 1 month, the mean number of visits/
patient (SD) was 10.7 (4.93), with a median (range) of 13 
visits (1–15). Overall, 150 follow-up visits were analyzed. 
The compliance of patients included in the study until their 
withdrawal or until the end of the study was good, with a 
median of 98.9% of treatment days with the correct intake 
of study medication.
Growth
Standard deviation scores for height and weight in the 11 
children with CAH treated with hydrocortisone granules 
for over 6 months were evaluated over the study period, 
and all but 1 showed normal growth with no trends for 
accelerated or reduced growth. The 1 patient with reduced 
growth had congenital renal hypoplasia in addition to 
CAH, which explained the poor growth. When adjusted for 
target height, two-thirds of the children converged towards 
their expected height centile (Fig. 1A). The mean difference 
between z-scores of actual height and target height (SD) 
decreased from 1.04 (0.71) to 0.89 (0.72). The z-scores for 
weight and BMI decreased toward the 50th percentile in 
half of the patients (Fig. 1B).
Safety and sick day rules
There were no deaths, no severe treatment-emergent ad-
verse events (TEAEs), no TEAEs leading to withdrawal 
from the study, and no TEAEs with a suspected causal re-
lationship to hydrocortisone granules. No cases of adrenal 
crisis were reported. Nine severe adverse events were re-
ported in 3 patients (gastroenteritis, vomiting, urinary tract 
infection, erysipelas), all considered unrelated to hydrocor-
tisone granules. A  total of 193 TEAEs were reported by 
14 subjects (77.8%), with the most commonly occurring 
of which were pyrexia, n  =  45 in 10 patients (45/10), 
gastroenteritis (15/9), viral upper respiratory tract infec-
tion (21/7), and vomiting (14/7). In 172/193 treatment-
emergent adverse events (13 subjects), and in all 9 severe 
adverse events, the hydrocortisone dose was increased 
using the sick day rules, and of these TEAEs 42 were re-
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of sick day episodes were fever, vomiting or diarrhea, re-
spiratory tract infections, or other (most commonly stress 
or excitement related symptoms or abdominal pain). In the 
subject with 42 episodes of implementing sick day rules, 
further investigation found that the parents were dosing 
for excitement and nonspecific abdominal pain on multiple 
occasions, for example, at a birthday party or New Year’s 
Eve. With the majority of TEAEs, the hydrocortisone dose 
was increased according to the sick day rules; in 7 cases the 
increased stress dose was given for 7 to 12 days, and in all 
other events the duration was less than 7 days.
Hydrocortisone dose
The hydrocortisone dose was within the recommended dose 
for body surface area over time, and at the lower end of the 
recommended treatment ranges for CAH at the end of the 
study (Table 3). Doses used at different time points varied 
from 0.5 to 10 mg, and the dose distribution varied from 
the beginning to the end of the study within age groups, 
with the older patients having a greater proportion of their 
dose in the morning and nighttime (Table 4).
Fludrocortisone dose
Daily fludrocortisone dose was divided into 1 to 3 single 
doses per day and adjusted according to the renin level 
(Table 3).
Monitoring by saliva and blood sampling
17-OHP salivary profiles were collected at home prior to 
82 of the 150 investigated visits (82/150; 54%). Of these 
82 investigated 17-OHP salivary profiles, the samples at all 
three daily dosing times were in range in 44% (36/82), the 
samples at 2 time points were in range in 28% (23/82), and 
at only 1 time point in 16% (13/82). In 12% (10/82), all 
three samples of the whole day 17-OHP profile were out of 
range. Hydrocortisone doses were changed in 40/150 visits, 
in 32 visits based on the results of salivary measurements 
collected at home before the visit, and in a further 8 visits due 
to serum 17-OHP levels. Of these 40 visits with change of 
hydrocortisone dose, in 21 visits a single dose was changed, 
in 13 visits 2 doses were changed, and in 6 visits all 3 doses 
of a day were changed, amounting to 65 dose changes in 
total. In 82%, the morning or nighttime dose was changed, 
resulting in an altered dose distribution across the day, with 
the lowering of the midday dose. In 12/32 cases, where the 
dose was adapted based on 17-OHP saliva sampling, a re-
peat sampling was done within 4 weeks, and in 8/12 cases 
these control samples were in range.
Discussion
We have prospectively studied a group of children with AI 
from 0 to nearly 8  years of age treated with hydrocorti-
sone granules for a total duration of up to 2.5 years. To 
our knowledge, this is the largest prospective interventional 
study to date in neonates, infants, and young children with 
Figure 1. Height and weight of individual patients at start and finish of 
study in patients that had more than 6 months of treatment (n = 11): A: 
Height standard deviation score (SDS) compared to parental target height. 
B: Weight SDS. *This child had renal hypoplasia in addition to CAH.
Table 2. Implementation of sick day rules
Cause Episodes Subjects Percentage of  
Subjects Overallc
Vomiting 14 5 28 
Fever 101 13 72 
Diarrhea 9 2 11 
Otherb 47 10 56
No reason given 1 1 6
Totala 172 13 72
a 42 episodes in 1 individual.
b Other causes are: Excitement/stress (birthday party, New Year´s Eve, 
Sleepover in kindergarten, first day at school), Abdominal pain, Infection, 
Injury (e.g., laceration, injury of teeth after fall), Headache, Exercise, 
Operation/Procedure, Rash
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AI. Individualized treatment by titration in these patients 
was in line with the treating center’s normal practice. The 
availability of a lowest unit dose of 0.5  mg allowed the 
doses to range from 0.5 to 10 mg at individual time points 
during the day. In 21.3% of all administrations, 0.5  mg 
doses were used. The daily dose per body surface area at 
the end of the study period across the patient group was 
at the lower end of that recommended for the treatment of 
CAH, and it was similar to that recommended for adrenal 
replacement therapy. Despite this relatively low dose, dis-
ease control remained good, as demonstrated by normal 
growth and the lack of pubertal development. The chil-
dren experienced common childhood illnesses, resulting in 
a large number of adverse events reported, none of which 
were considered related to the study medication, and no 
adrenal crises occurred.
Recommended hydrocortisone dosing for children with 
CAH is 10 to 15 mg/m2/day, given 3 times daily, although 
cohort studies show higher doses generally being used in 
children (14–16). In this study, accurate dosing with hydro-
cortisone granules using dose changes down to 0.5  mg 
allowed for dosing at the lower end of the recommended 
dose range. The thrice daily, individualized, 8-hour dosing 
regimen used in this study has been used for many years 
in the main center. While it appears clear that twice daily 
dosing is less effective in the attainment of physiological 
cortisol concentrations than thrice daily dosing, no evidence 
to date has shown a benefit for differently timed regimens 
for hydrocortisone delivery (14). Pharmacokinetic studies 
of hydrocortisone in children with AI reveal significant 
times of high and low cortisol exposure, with frequently 
very low cortisol levels between dosing (17); therefore, this 
was also likely in this study.
This is the first prospective study in young children of 
stress dosing and adrenal crisis and demonstrates that chil-
dren with AI under 8 years of age encountered multiple 
intercurrent illnesses; however, despite the hydrocortisone 
dose being towards the lower end of the recommended 
dose range, no adrenal crises were seen during this period. 
Congenital adrenal hyperplasia has been associated with 
increased risk of mortality. In a cohort of 588 patients with 
CAH from the Swedish national registry, adrenal crisis 
has been reported as the leading cause of death followed 
by cardiovascular disease, which is the leading cause of 
death in adults globally (18). Prevention of adrenal crises 
in CAH patients is 1 of the key elements of appropriate 
glucocorticoid dosing under normal and stress-related 
situations (14), and the main risk of lowering doses of 
steroid in conditions with AI is the possible increase in life 
threatening adrenal crises. A  long-term study of adrenal 
Table 4. Average dose and dose distribution of 
hydrocortisone (morning – afternoon – nighttime dose) 


















46 – 22 – 32 2.3 – 1.1 – 1.6 0 – 7 – 10




2.6 – 1.2 – 2.6 41 – 18 – 23
Children aged 4 to 
8.4 years
36 – 14 – 50 3.2 – 1.3 – 4.6 18 – 43 – 15
Abbreviation: HC, hydrocortisone.
a Half of the patients were treated with a hydrocortisone dose of 2-2-2 mg 
and half of the patients were treated with 1-1-1 mg, resulting in a mean dose 
of 1.5-1.5-1.5 mg.
Table 3. Daily dose of hydrocortisone and fludrocortisone at the beginning and end of study in different age groups, median 
(range), and number
Visit Cohort 1 Cohort 2 Cohort 3 Overall
First visit
HC dose (mg/m2/day), median (range) 11.9 (7.20–15.5) 9.9 (8.6–12.2) 12.0 (11.1–29.5) 11.4 (7.2–29.5)
N 9 4 3 16
FC dose (µg/m2/day), median (range) 102 (62–159) 146 (124–180) 492 (369–900) 127 (62–900)
N 9 4 3 16
Last visit
HC dose (mg/m2/day), median (range) 10.2 (7.0–14.4) 9.8 (8.9–13.1) 8.6 (8.2–13.7) 9.7 (7.0–14.4)
N 4 4 3 11
FC dose (µg/m2/day), median (range) 61 (45–77) 70 (65–94) 213 (92–216) 72 (45–216)
N 4 4 3 11
The 3 cohorts were classified according to age at study entry in a previous study. Cohort 1: 2 to <6 years; cohort 2: 1 month to 2 years; and cohort 3: <28 days.
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crises in patients with CAH found that receiving lower 
hydrocortisone doses had associated higher rates of stress 
dosing and illnesses and were a risk factor for adrenal 
crises (19). Patients with CAH and AI and their caregivers 
are taught sick day rules (20), and they are recommended 
to increase their glucocorticoid intake by doubling, trip-
ling, or 5-fold, increasing the dose whenever they feel un-
well with a fever or flu-like illness. In case of vomiting, 
diarrhea, or severe worsening of illness a prednisolone sup-
pository should be used or an injection of hydrocortisone 
is recommended. There is no universally accepted regimen 
of sick day rules. The protocol used in this study, according 
to the German CAH guidelines, has been successfully used 
by the main study center (Charité Universitaetsmedizin 
Berlin) for several years, and it worked well for the study 
cohort. Up until recently, very little information on the 
underlying causes that prompt parents to institute stress 
dosing have been assessed systematically. A retrospective 
study of El-Maouche et al found an increased number of 
illnesses and necessary stress dosing in children compared 
with adults, with the highest rates found in younger chil-
dren, in particular (19). The follow-up period of our study 
allowed us to gather such data, with adverse events and 
stress dosing discussed during the regular visits every 3 
months, and it was reassuring that in most cases the stress 
dosing was being used for physiological stresses. However, 
1 patient in this cohort had an excess number of events 
treated with stress dosing and higher doses were adminis-
tered, for example, for excitement and nonspecific abdom-
inal pain on multiple occasions. We believe that gathering 
data on stress dosing can help pediatric endocrinologists 
to identify families where stress dosing is being used more 
frequently than expected and where counseling and sup-
port can be instituted to avoid the child being exposed to 
excessive steroid doses.
The drop-out rate in the study can be explained by 2 
major factors, depending on age of the children. In neo-
nates, patients were recruited from all over Germany and 
parents were not willing to travel the long distance to the 
study center in the follow-up study. In children >2 years of 
age, those withdrawing generally did not accept the change 
to a nonsweetened hydrocortisone medication, and so 
withdrew early. In the remaining study cohort, compliance 
was high, with a median of >98% of treatment days where 
study medication was administered as recommended, and 
this might reflect the clinic’s approach of patient empower-
ment and education of the patients, parents, and caregivers.
Therapy was predominantly monitored by salivary pro-
files. If parents provided a child’s salivary 17-OHP profile 
before the clinic visit, we did not perform serum 17-OHP. 
However, at the yearly blood sample to check for renin values, 
we always measured serum testosterone and 17-OHP. These 
blood samples are not timed and, therefore, in our experi-
ence, of limited value as sometimes the serum 17-OHP is 
increased despite the 17-OHP home salivary profile 2 days 
before being in range. This might be due to blood sampling 
inducing an increase in 17-OHP. Additionally, it is difficult to 
adjust individual doses during the day according to a single 
serum 17-OHP measurement. When dosing was adjusted 
by 17-OHP salivary profile, the hydrocortisone dose before 
each sampling time point was evaluated and changed as re-
quired. When dosing was adapted by the serum 17-OHP 
measurement, the overall dose was adjusted according to 
the international guidelines by calculating the dose by 10 to 
15 mg/m2 body surface area divided into 3 single doses (14). 
The monitoring of CAH is an area where little data exists 
to provide practice guidelines. According to our experience, 
salivary sampling in young children worked well, with sal-
ivary profiles available at more than half of the clinic visits, 
so that blood sampling could be minimized. Monitoring by 
17-OHP salivary profiles was started at 3–6 months of age. 
An advantage of 17-OHP saliva sampling is that the collec-
tion can be performed at home without further stress for the 
children, and it allows for individual titration of therapy for 
each patient. However, more research is required to develop 
best practice guidance on monitoring in CAH, with our data 
suggesting that salivary sampling can be considered as a vi-
able alternative to blood sampling.
Based on our findings from this study, which is the largest 
interventional study in the orphan condition of childhood 
AI to date, the use of hydrocortisone granules resulted in ef-
fective treatment of the children’s AI, as demonstrated by the 
absence of adrenal crises and a normal growth profile. No 
safety issues were detected. Over the course of 2.5 years, the 
patients’ doses of hydrocortisone remained stable and within 
the recommended range, and they decreased at the end of the 
study to the lower end of the recommended treatment range 
for CAH. In conclusion, hydrocortisone granules are an ef-
fective treatment for childhood AI, providing the ability to 
accurately prescribe pediatric-appropriate doses.
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